TR199500299A2 - Farmasötik bilesimler. - Google Patents

Farmasötik bilesimler.

Info

Publication number
TR199500299A2
TR199500299A2 TR97/00299A TR9500299A TR199500299A2 TR 199500299 A2 TR199500299 A2 TR 199500299A2 TR 97/00299 A TR97/00299 A TR 97/00299A TR 9500299 A TR9500299 A TR 9500299A TR 199500299 A2 TR199500299 A2 TR 199500299A2
Authority
TR
Turkey
Prior art keywords
macrolide
provides
pharmaceutical compositions
dimethyisosorbide
cyclosporine
Prior art date
Application number
TR97/00299A
Other languages
English (en)
Inventor
Dr Sylvain Cottens
Dr Barbara Haeberlin
Dr Richard Sedrani
Dr Jacky Vonderscher
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9421613A external-priority patent/GB9421613D0/en
Priority claimed from GB9422084A external-priority patent/GB9422084D0/en
Priority claimed from GBGB9425353.1A external-priority patent/GB9425353D0/en
Priority claimed from GBGB9517133.6A external-priority patent/GB9517133D0/en
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Publication of TR199500299A2 publication Critical patent/TR199500299A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Colloid Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
TR97/00299A 1994-10-26 1995-10-26 Farmasötik bilesimler. TR199500299A2 (tr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9421613A GB9421613D0 (en) 1994-10-26 1994-10-26 Organic compounds
GB9422084A GB9422084D0 (en) 1994-11-02 1994-11-02 Organic compounds
GBGB9425353.1A GB9425353D0 (en) 1994-12-15 1994-12-15 Organic compounds
GBGB9517133.6A GB9517133D0 (en) 1995-08-22 1995-08-22 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
TR199500299A2 true TR199500299A2 (tr) 1997-06-23

Family

ID=27451224

Family Applications (2)

Application Number Title Priority Date Filing Date
TR95/01321A TR199501321A2 (tr) 1994-10-26 1995-10-26 Farmasötik bilesimler.
TR97/00299A TR199500299A2 (tr) 1994-10-26 1995-10-26 Farmasötik bilesimler.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR95/01321A TR199501321A2 (tr) 1994-10-26 1995-10-26 Farmasötik bilesimler.

Country Status (25)

Country Link
EP (2) EP2039358A1 (tr)
JP (3) JPH10509699A (tr)
KR (2) KR100518135B1 (tr)
CN (3) CN1124157C (tr)
AT (1) ATE411800T1 (tr)
AU (1) AU714360B2 (tr)
BR (1) BR9509496A (tr)
CA (1) CA2200967C (tr)
CY (1) CY2210B1 (tr)
CZ (1) CZ289838B6 (tr)
DE (2) DE69535869D1 (tr)
ES (1) ES2316150T3 (tr)
FI (1) FI119497B (tr)
HU (1) HU225535B1 (tr)
IL (3) IL115742A (tr)
MY (1) MY129435A (tr)
NO (2) NO323078B1 (tr)
NZ (1) NZ295655A (tr)
PE (1) PE52896A1 (tr)
PL (1) PL184368B1 (tr)
PT (1) PT787011E (tr)
SK (2) SK286178B6 (tr)
TR (2) TR199501321A2 (tr)
TW (1) TW308544B (tr)
WO (1) WO1996013273A1 (tr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
NZ280689A (en) * 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
US5958876A (en) * 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
EP0978288A4 (en) * 1997-04-11 2006-07-12 Astellas Pharma Inc DRUG COMPOSITION
IN188719B (tr) * 1997-09-08 2002-11-02 Panacea Biotec Ltd
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
CA2313024C (en) 1997-12-10 2008-06-03 Severson, Mary L. Pharmaceutical compositions containing an omega-3 fatty acid oil
GB2380673B (en) * 1998-03-06 2003-05-28 Novartis Ag Emulsion preconcentrates containing cyclosporin or a macrolide
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
AU3843999A (en) * 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
TWI241915B (en) * 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
SE9804192D0 (sv) * 1998-12-03 1998-12-03 Scotia Lipidteknik Ab New formulation
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
CN1151782C (zh) * 1999-01-28 2004-06-02 迪内希·尚蒂拉尔·帕特尔 一种具有哺乳动物麻醉的诱导和保持以及镇静用途的药用注射液
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU4565000A (en) 1999-05-10 2000-11-21 Novartis Ag Organic compounds
GB9912476D0 (en) 1999-05-28 1999-07-28 Novartis Ag Organic compounds
DE19925001A1 (de) * 1999-05-31 2000-12-07 Pharma Concepts Gmbh & Co Kg Flüssiges Konzentrat
ATE251449T1 (de) 1999-06-14 2003-10-15 Cosmo Spa Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
KR100342942B1 (ko) * 1999-07-05 2002-07-02 민경윤 카르두스 마리아누스 추출물 또는 이로부터 정제된 실리빈을함유하는 경구용 마이크로에멀젼 조성물
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7919113B2 (en) 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
MXPA02004900A (es) * 2000-09-18 2003-10-24 Rpg Life Sciences Ltd Formulacion autoemulsificable, con mejores actividades de bioabsorcion e inmunosupresion.
JP2002193790A (ja) * 2000-12-27 2002-07-10 Lion Corp 水難溶性薬剤含有水中油型エマルジョン及びその製造方法
PT2269603E (pt) 2001-02-19 2015-09-09 Novartis Ag Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
CN100346785C (zh) * 2001-10-25 2007-11-07 迪内希尚蒂拉尔·帕特尔 选择性环氧化酶ⅱ抑制剂的新型制剂
BR0313024A (pt) 2002-07-30 2005-07-12 Wyeth Corp Formulações parenterais contendo um hidroxiéster de rapamicina
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
CN100381175C (zh) * 2004-10-09 2008-04-16 山西中医学院 一种微乳制剂及其制备方法
CN101185638B (zh) * 2004-10-09 2011-04-06 山西中医学院 一种微乳制剂及其制备方法
GB0504950D0 (en) * 2005-03-10 2005-04-20 Novartis Ag Organic compositions
CN1872058B (zh) * 2005-05-31 2011-03-30 华北制药集团新药研究开发有限责任公司 一种含大环内酯类化合物的药物组合物
SI2275103T1 (sl) 2005-11-21 2014-07-31 Novartis Ag mTor inhibitorji pri zdravljenju endokrinih tumorjev
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
CN1919194A (zh) * 2006-08-17 2007-02-28 刘瑜玲 西罗莫司的液体组合物
JP5450092B2 (ja) 2006-12-29 2014-03-26 アボット・ラボラトリーズ 全血中の分子または薬物の検出のための診断検査
EP2118657B1 (en) 2006-12-29 2014-05-21 Abbott Laboratories Non-denaturing lysis reagent for use with capture-in-solution immunoassay
ES2393135T3 (es) 2006-12-29 2012-12-18 Abbott Laboratories Ensayo mejorado para fármacos inmunosupresores
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
US10485792B2 (en) 2009-08-26 2019-11-26 Hadasit Medical Research Services & Development Limited Sustained release delivery systems for the prevention and treatment of head and neck cancers
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
SG11201405848UA (en) 2012-03-23 2014-10-30 Univ Queensland Immunomodulatory agent and uses therefor
WO2014184734A1 (en) 2013-05-14 2014-11-20 Novartis Ag Markers associated with mtor inhibition
WO2015044854A1 (en) 2013-09-24 2015-04-02 Novartis Ag Markers associated with mtor inhibition
CN103933546A (zh) * 2014-03-27 2014-07-23 北京科技大学 雷帕霉素与环孢素a纳米口服微乳液制备方法
JP7459458B2 (ja) 2018-06-28 2024-04-02 ライオン株式会社 内服組成物及びその製造方法
WO2023139907A1 (ja) * 2022-01-24 2023-07-27 株式会社Moresco 防腐効果を付与したナノエマルジョン

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1274354A (fr) 1956-03-10 1961-10-27 Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol
US3244592A (en) 1962-06-09 1966-04-05 Arai Tadashi Ascomycin and process for its production
GB1380741A (en) * 1971-02-05 1975-01-15 Squibb & Sons Inc Antibiotic compositions and their preparation
GB1322306A (en) * 1971-04-15 1973-07-04 Meiji Seika Co Stabilized antibiotic preparation and manufacturing process therefor
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
JPS59104326A (ja) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
JPS60163823A (ja) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd 経口投与製剤
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
DK0427680T3 (da) 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
DE9208647U1 (tr) 1992-06-27 1992-09-24 Rademacher, Antje, 4980 Buende, De
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5234140A (en) 1992-07-28 1993-08-10 S. C. Johnson & Son, Inc. Re-useable aerosol container
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
CZ278863B6 (en) 1992-09-07 1994-07-13 Galena Medicinal preparations with n-methylated cyclic undecapeptides
PT589843E (pt) * 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
FR2697040B1 (fr) 1992-10-21 1994-12-30 Ind Entreprise Elément de protection contre le bruit et son utilisation.
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
SI0649651T1 (en) * 1993-09-28 2001-02-28 Scherer Gmbh R P Soft gelatin capsule manufacture
AU688782B2 (en) * 1993-09-30 1998-03-19 Wyeth Rapamycin formulations for oral administration
WO1995014023A1 (en) 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators

Also Published As

Publication number Publication date
CY2210B1 (en) 2002-11-08
WO1996013273A1 (en) 1996-05-09
TR199501321A2 (tr) 1996-06-21
DE19581805T1 (de) 1997-10-16
SK285809B6 (sk) 2007-08-02
NO323063B1 (no) 2006-12-27
ES2316150T3 (es) 2009-04-01
SK52197A3 (en) 1997-09-10
NO323078B1 (no) 2006-12-27
CN1124157C (zh) 2003-10-15
DE69535869D1 (de) 2008-12-04
JP2004359696A (ja) 2004-12-24
JP2005247870A (ja) 2005-09-15
MX9702701A (es) 1997-10-31
AU714360B2 (en) 1999-12-23
NO20031901D0 (no) 2003-04-28
BR9509496A (pt) 1997-09-30
FI119497B (fi) 2008-12-15
KR100518135B1 (ko) 2005-10-04
HUT76858A (en) 1997-12-29
KR100541198B1 (ko) 2007-04-11
IL115742A0 (en) 1996-01-19
FI970995A0 (fi) 1997-03-10
AU3924895A (en) 1996-05-23
NO971898D0 (no) 1997-04-24
IL129547A (en) 2001-01-11
PE52896A1 (es) 1996-12-12
NZ295655A (en) 1998-12-23
NO971898L (no) 1997-06-24
CZ289838B6 (cs) 2002-04-17
PT787011E (pt) 2009-01-23
TW308544B (tr) 1997-06-21
PL319691A1 (en) 1997-08-18
IL129547A0 (en) 2000-02-29
JPH10509699A (ja) 1998-09-22
EP0787011B1 (en) 2008-10-22
EP0787011A1 (en) 1997-08-06
SK286178B6 (sk) 2008-04-07
HU225535B1 (en) 2007-02-28
FI970995A (fi) 1997-04-25
KR970706837A (ko) 1997-12-01
CN1679938A (zh) 2005-10-12
CN1404833A (zh) 2003-03-26
KR20040074104A (ko) 2004-08-21
PL184368B1 (pl) 2002-10-31
CA2200967C (en) 2007-09-25
CA2200967A1 (en) 1996-05-09
CZ123197A3 (en) 1997-07-16
EP2039358A1 (en) 2009-03-25
IL115742A (en) 2000-06-01
NO20031901L (no) 1997-06-24
ATE411800T1 (de) 2008-11-15
CN1161652A (zh) 1997-10-08
MY129435A (en) 2007-04-30

Similar Documents

Publication Publication Date Title
TR199500299A2 (tr) Farmasötik bilesimler.
CA2320182A1 (en) Compositions containing organic compounds
DK0948965T3 (da) Stabile medicinske præparater indeholdende 4,5-epoxymorphinanderivater
CA2338358A1 (en) Compounds and compositions for delivering active agents
DE59409644D1 (de) Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
BR9407002A (pt) Preparados farmacêuticos para agentes ativos fracamente solúveis
CA2133175A1 (en) Rapamycin formulations for oral administration
ES2201644T3 (es) Composicion farmaceutica a base de estrogeno y de progesterona.
WO2000020019A3 (en) A composition for the prevention and/or treatment of atherosclerosis
DE69808911D1 (de) Verfahren zum lösen von pharmazeutischen wirkstoffen in wasser und in wässrige träger
CA2366679A1 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
NL300055I2 (nl) Rapamycinepreparaten voor orale toediening.
BR9809708A (pt) Composições farmacêuticas de peptìdeos tendo solubilidade baixa em meio fisiológico
ECSP951565A (es) Composiciones farmaceuticas
CY1109190T1 (el) Φαρμακευτικα σκευασματα για παρεντερικη χορηγηση τα οποια περιεχουν εποθιλονη